Biocon Limited (NSE: BIOCON | BSE: 532523)
Source: Biocon Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Biocon Limited is an innovation-led, fully integrated global biopharmaceutical enterprise committed to enhancing global health equity by expanding access to high-quality, affordable biopharmaceuticals, complex generics, peptides, and research services. Biocon operates across the biopharmaceutical value chain, integrating advanced R&D, large-scale fermentation and cell-culture manufacturing, global regulatory navigation, and direct-to-market commercialization across advanced and emerging economies.
- Biosimilars Portfolio (12 Commercialized Asset Family): Includes biosimilar Insulin Glargine (Semglee® / Basalog®), biosimilar Insulin Aspart (Kirsty™), recombinant human insulin (Insugen®), biosimilar Trastuzumab (Ogivri®), biosimilar Pegfilgrastim (Fulphila®), biosimilar Bevacizumab (Abevmy®), biosimilar Adalimumab (Hulio®), biosimilar Etanercept, biosimilar Ustekinumab (Yesintek®), biosimilar Aflibercept (Yesafili®), and biosimilar Denosumab (Bosaya™ / Aukelso™ / Vevzuo®).
- Generics & Peptides Portfolio: Commercial formulations and APIs across immunosuppressants (Tacrolimus, Everolimus, Mycophenolate), statins (Atorvastatin, Simvastatin, Rosuvastatin), specialty cardiovascular and CNS agents, and generic GLP-1 receptor agonists (Liraglutide commercialized in Europe/UK; Semaglutide global filings under execution).
- Operational KPIs & Capacity Utilization: Total fermentation API capacity exceeds 3,500+ KL across India sites; oral solid dosage (OSD) capacity reaches 880 million units per year (augmented by the Cranbury, New Jersey facility); mammalian and microbial biologics drug substance capacity exceeds 300+ KL; injectable drug product capacity stands at 100+ million units annually. The Malaysia insulins site is currently undergoing expansion to double drug substance and drug product capacities.
- Customer Concentration & Raw Material Sourcing: In accordance with Ind AS 108 disclosures, no single external commercial customer accounted for more than 10% of Biocon’s consolidated revenue in FY26. Indigenization programs reduced raw material import dependencies, with local procurement initiatives spanning 484 indirect suppliers in Biosimilars and 13 key direct suppliers in Generics.
📋 Quick Facts / Company Snapshot: Biocon Limited (NSE: BIOCON | BSE: 532523)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Biocon Limited |
| Corporate Identity Number (CIN) | L24234KA1978PLC003417 |
| International Securities Identification Number (ISIN) | INE376G01013 |
| Stock Exchange Listing | National Stock Exchange of India Limited (Symbol: BIOCON) | BSE Limited (Scrip Code: 532523) |
| Date of Incorporation / Founding Year | 1978 |
| Founders / Key Founding Figures | Kiran Mazumdar-Shaw |
| Registered Office & Corporate Headquarters | 20th KM, Hosur Road, Electronic City, Bengaluru – 560 100, Karnataka, India |
| Telephone & Official Contact Email | Tel: +91 80 2808 2808 | Email: co.secretary@biocon.com |
| Executive Chairperson | Kiran Mazumdar-Shaw |
| Chief Executive Officer & Managing Director | Shreehas Pradeep Tambe (w.e.f. April 01, 2026) |
| Chief Financial Officer | Kedar Narayan Upadhye (w.e.f. April 01, 2026) |
| Company Secretary & Compliance Officer | Rajesh U. Shanoy |
| Promoter Group | Kiran Mazumdar-Shaw, Prof. Ravi Rasendra Mazumdar, Dev Mazumdar, Glentec International Limited |
| Industry / Sector Classification | Biopharmaceuticals & Biotechnology (NIC Code 021: Manufacture of pharmaceuticals, medicinal chemical, and botanical products) |
| Total Workforce & Human Capital | 9,725 permanent employees (excluding contractors; 28% female representation in combined workforce) |
| Manufacturing Facilities & Footprint | Domestic Sites: Bengaluru (Karnataka), Visakhapatnam (Andhra Pradesh), Hyderabad (Telangana); International Sites: Johor (Malaysia), Cranbury (New Jersey, USA) |
| Credit Ratings (Domestic & Global) | CRISIL: CRISIL AA+/Stable (Long-Term), CRISIL A1+ (Short-Term) | ICRA: [ICRA]AA+(Stable) / [ICRA]A1+ | India Ratings: IND AA+/Stable / IND A1+ | S&P / Fitch Global Ratings |
| Statutory Auditors | B S R & Co. LLP (outgoing FY26); S. R. Batliboi & Associates LLP (recommended for 5-year term from FY27 to FY31) |
| Secretarial & Cost Auditors | M/s. V. Sreedharan & Associates (Secretarial Auditors) | M/s. Rao, Murthy & Associates (Cost Auditors) |
| Registrar and Share Transfer Agent (RTA) | KFin Technologies Limited (Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad – 500 032) |
🏢 The Corporate Identity: Biocon Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Biocon Limited is an innovation-led, fully integrated global biopharmaceutical enterprise committed to enhancing global health equity by expanding access to high-quality, affordable biopharmaceuticals, complex generics, peptides, and research services. Biocon operates across the biopharmaceutical value chain, integrating advanced R&D, large-scale fermentation and cell-culture manufacturing, global regulatory navigation, and direct-to-market commercialization across advanced and emerging economies.
The enterprise functions through two complementary operational pillars: products and services. The products segment encompasses an industry-leading portfolio of biosimilars (monoclonal antibodies, recombinant human insulins, and insulin analogs) alongside complex generic formulations and active pharmaceutical ingredients (APIs), with a specialized focus on GLP-1 peptide therapies for diabesity. The services segment is anchored by its listed subsidiary, Syngene International Limited, which delivers end-to-end contract research, development, and manufacturing organization (CRDMO) solutions to global life sciences partners.
- Unified Global Biopharma Platform: The structural integration of Biocon Biologics Limited into Biocon Limited in FY26 created a single, consolidated biopharmaceutical platform (“OneBiocon”), eliminating multi-tiered corporate complexity and streamlining capital allocation.
- Focus on Chronic Disease Ecosystems: Strategic R&D and commercialization are concentrated in high-burden, high-value therapeutic categories—diabetes, oncology, immunology, ophthalmology, and bone health—which represent nearly 40% of global biopharmaceutical expenditure.
- Access-Led Innovation at Scale: Biocon combines proprietary microbial (Pichia pastoris and E. coli) and mammalian cell-culture platforms with global-scale infrastructure, serving over 23 million patients annually across 120+ countries.
The Founders, Promoters & Their Legacy
Biocon was founded in 1978 by Kiran Mazumdar-Shaw as a pioneer industrial enzymes venture in a garage in Bengaluru. Over nearly five decades, under her leadership as Executive Chairperson, Biocon transformed into India’s premier biotechnology company and a global biopharmaceutical leader. A first-generation entrepreneur, Kiran Mazumdar-Shaw has shaped India’s bioeconomy policies, serving on global advisory boards and receiving national honors, including the Padma Shri (1989) and Padma Bhushan (2005), alongside global recognitions such as the EY World Entrepreneur of the Year (2020) and election to the U.S. National Academy of Engineering.
The promoter group, comprising Kiran Mazumdar-Shaw, Prof. Ravi Rasendra Mazumdar, Dev Mazumdar, and Glentec International Limited, holds a collective 44.91% equity stake in the Company as of March 31, 2026. Prof. Ravi Mazumdar, a Non-Executive Director, brings deep technical expertise at the intersection of AI, machine learning, and stochastic network systems. The leadership structure underwent a planned evolution in FY26, with Shreehas Pradeep Tambe—a 29-year Biocon veteran who previously spearheaded the integration of Viatris’ global biosimilars business—assuming the role of Chief Executive Officer & Managing Director of Biocon Limited effective April 01, 2026.
The Journey: Corporate History & Key Milestones
Biocon’s historical trajectory reflects a deliberate evolution from specialty enzymes to small-molecule fermentation APIs, biopharmaceuticals, biosimilars, and integrated global commercial platforms:
- 1978–1990s (Enzyme Pioneer to Biopharmaceutical Ambition): Established as a joint venture with Biocon Biochemicals of Ireland; commercialized industrial enzymes and developed proprietary bioprocess technologies using solid-state fermentation.
- 2000–2006 (Insulin Break-Through & IPO): Developed and commercialized India’s first indigenous recombinant human insulin (Insugen®) using proprietary Pichia pastoris technology. Successfully completed an oversubscribed Initial Public Offering (IPO) in 2004. Launched Syngene as a custom research subsidiary.
- 2006–2015 (Oncology Leadership & Global Partnerships): Introduced Biomab EGFR® (Nimotuzumab), India’s first indigenous monoclonal antibody, followed by the global commercial launch of biosimilar Trastuzumab (CANMAb™). Established Asia’s largest integrated insulin manufacturing facility in Johor, Malaysia.
- 2016–2021 (Regulated Market Breakthroughs): Secured historic U.S. FDA approvals for biosimilar Trastuzumab (Ogivri®) and biosimilar Pegfilgrastim (Fulphila®). Achieved the world’s first interchangeable biosimilar approval from the U.S. FDA for Insulin Glargine (Semglee®), followed by interchangeable Insulin Aspart (Kirsty™).
- 2022–2026 (Global Integration & Peptides Expansion): Acquired Viatris’ global biosimilars business for USD 3.3 billion, creating a direct commercial footprint across 120+ markets. Executed a comprehensive equity recapitalization raising ₹ 8,650.00 Crores through two QIP tranches, fully absorbing minority interests to make Biocon Biologics a wholly-owned subsidiary and unifying the group into OneBiocon. Launched generic Liraglutide in the UK and Europe, initiating global filings for generic Semaglutide.
The Corporate Umbrella & Group Structure
The operational and corporate architecture of Biocon Limited encompasses direct operations, wholly-owned biopharmaceutical subsidiaries, and listed service entities. The corporate structure as of March 31, 2026, is outlined below:
| Entity Name | Jurisdiction / Country | Economic Ownership (%) | Primary Business Function |
|---|---|---|---|
| Biocon Limited | India | Parent / Listed Entity | Generic Formulations, Peptides (GLP-1), Small Molecule APIs, Group Holding Company |
| Biocon Biologics Limited (BBL) | India | 99.00% (to reach 100%) | Global Biosimilars, Recombinant Insulins, Monoclonal Antibodies, Novel Biologics |
| Syngene International Limited | India | 53.88% (Subsidiary) | Contract Research, Development and Manufacturing Organization (CRDMO) |
| Biocon Sdn. Bhd. | Malaysia | 100.00% (via BBL) | Commercial-scale Recombinant Insulin Substance & Drug Product Manufacturing |
| Biocon Pharma Inc. / Biocon Generics Inc. | United States | 100.00% (via BL) | U.S. Formulations Distribution, Cranbury OSD Manufacturing Operations |
| Biocon Biologics Inc. / Biocon Biologics UK PLC | USA / United Kingdom | 100.00% (via BBL) | Advanced Markets Commercial Operations, Regulatory Compliance, & Global IP Holding |
| Bicara Therapeutics Inc. | United States | 10.10% (Associate / Investment) | Nasdaq-listed Immuno-Oncology Biotech developing Ficerafusp Alfa (Breakthrough Therapy) |
⚙️ The Business Engine: Biocon Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Biocon structures its consolidated business operations into three primary reporting segments under Ind AS 108: Biosimilars, Generics, and CRDMO (Services). In FY26, consolidated Revenue from Operations expanded by 11% year-on-year to reach ₹ 16,927.00 Crores (compared to ₹ 15,261.70 Crores in FY25), driven by robust execution in advanced market biosimilars and underlying momentum in complex generics.
| Business Segment | FY 2025-26 Revenue (₹ Cr) | % Share of Total Revenue | FY 2024-25 Revenue (₹ Cr) | Segment Results / PBT (FY26 ₹ Cr) | Segment Results / PBT (FY25 ₹ Cr) | Latest YoY (%) |
|---|---|---|---|---|---|---|
| Biosimilars | 10,431.20 | 60.89% | 9,017.40 | 587.60 | 1,196.10 | +15.68% |
| Generics | 3,168.10 | 18.50% | 3,017.50 | (134.80) | 175.50 | +4.99% |
| CRDMO (Syngene) | 3,738.70 | 21.82% | 3,642.40 | 487.50 | 627.90 | +2.64% |
| Inter-Segment Eliminations | (411.00) | -2.40% | (415.60) | (89.50) | (209.40) | -1.11% |
| Total Revenue from Operations | 16,927.00 | 100.00% | 15,261.70 | 850.80 | 1,790.10 | +10.91% |
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
Biocon’s product catalog spans high-complexity biological therapies, synthetic and fermentation-derived small molecules, peptide formulations, and integrated contract research services:
- Biosimilars Portfolio (12 Commercialized Asset Family): Includes biosimilar Insulin Glargine (Semglee® / Basalog®), biosimilar Insulin Aspart (Kirsty™), recombinant human insulin (Insugen®), biosimilar Trastuzumab (Ogivri®), biosimilar Pegfilgrastim (Fulphila®), biosimilar Bevacizumab (Abevmy®), biosimilar Adalimumab (Hulio®), biosimilar Etanercept, biosimilar Ustekinumab (Yesintek®), biosimilar Aflibercept (Yesafili®), and biosimilar Denosumab (Bosaya™ / Aukelso™ / Vevzuo®).
- Generics & Peptides Portfolio: Commercial formulations and APIs across immunosuppressants (Tacrolimus, Everolimus, Mycophenolate), statins (Atorvastatin, Simvastatin, Rosuvastatin), specialty cardiovascular and CNS agents, and generic GLP-1 receptor agonists (Liraglutide commercialized in Europe/UK; Semaglutide global filings under execution).
- Operational KPIs & Capacity Utilization: Total fermentation API capacity exceeds 3,500+ KL across India sites; oral solid dosage (OSD) capacity reaches 880 million units per year (augmented by the Cranbury, New Jersey facility); mammalian and microbial biologics drug substance capacity exceeds 300+ KL; injectable drug product capacity stands at 100+ million units annually. The Malaysia insulins site is currently undergoing expansion to double drug substance and drug product capacities.
- Customer Concentration & Raw Material Sourcing: In accordance with Ind AS 108 disclosures, no single external commercial customer accounted for more than 10% of Biocon’s consolidated revenue in FY26. Indigenization programs reduced raw material import dependencies, with local procurement initiatives spanning 484 indirect suppliers in Biosimilars and 13 key direct suppliers in Generics.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Semglee® / Basalog® | Biosimilars (Diabetes) | First interchangeable biosimilar Insulin Glargine in the U.S.; market leader across emerging economies. |
| Kirsty™ | Biosimilars (Diabetes) | First and only interchangeable rapid-acting biosimilar Insulin Aspart approved in the U.S. |
| Ogivri® | Biosimilars (Oncology) | Biosimilar Trastuzumab for HER2-positive breast and gastric cancers; leading market share in key geographies. |
| Fulphila® | Biosimilars (Oncology) | Biosimilar Pegfilgrastim for reducing chemotherapy-induced neutropenia infection risks. |
| Yesintek® | Biosimilars (Immunology) | Biosimilar Ustekinumab for Crohn’s disease and psoriasis; over 70% commercial access coverage in the U.S. |
| Yesafili® | Biosimilars (Ophthalmology) | Biosimilar Aflibercept for age-related macular degeneration; launched in Canada and Europe. |
| Bosaya™ / Aukelso™ | Biosimilars (Bone Health / Oncology) | Biosimilar Denosumab targeting osteoporosis and cancer-related bone loss; approved in U.S. & EU. |
| Liraglutide / Semaglutide | Complex Generics (Peptides) | Generic GLP-1 peptide formulations for diabesity, launched in UK/EU with pending U.S. filings. |
Mapping the Domestic & Global Reach (India vs. Exports)
Biocon operates a globally diversified commercial infrastructure, deriving over 94% of its consolidated operating revenues from international markets. Commercial operations cover advanced regulated markets (North America, Europe, Japan, Australia) and key emerging markets across LATAM, AFMET, and APAC.
| Geographic Market | FY 2025-26 Revenue (₹ Cr) | % Share of Total Revenue | FY 2024-25 Revenue (₹ Cr) | Key Countries & Operational Highlights | Latest YoY (%) |
|---|---|---|---|---|---|
| United States of America | 7,994.80 | 47.23% | 7,042.30 | Direct commercial sales of biosimilars & ANDAs; CalRx Glargine partnership in California. | +13.53% |
| European Union & UK | 4,616.70 | 27.27% | 3,848.10 | Direct & partner-led commercialization of 12 biosimilars; generic Liraglutide launches. | +19.97% |
| Rest of the World (RoW) | 3,397.70 | 20.07% | 3,394.80 | Strong insulin & oncology presence in Brazil, LATAM, AFMET, APAC, and Malaysia. | +0.09% |
| India (Domestic) | 917.80 | 5.42% | 976.50 | Focused API supplies & Syngene domestic services (adjusted for BFI divestment). | -6.01% |
| Total Revenue from Operations | 16,927.00 | 100.00% | 15,261.70 | Servicing 120+ global countries across all five major continents. | +10.91% |
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
Biocon has built a robust manufacturing and research network spanning India, Malaysia, North America, and Europe. All core facilities hold active cGMP approvals from leading global regulatory authorities, including the U.S. FDA, EMA (Europe), Health Canada, PMDA (Japan), ANVISA (Brazil), and MHRA (UK):
- Bengaluru Campus (Electronic City & Hebbagodi, Karnataka): Headquarters, central biopharmaceuticals R&D center, small molecule fermentation API plants, mammalian cell-culture drug substance suites, and fill-finish injectable lines.
- Visakhapatnam Facility (Andhra Pradesh): Large-scale fermentation API manufacturing complex catering to global immunosuppressant and statin supplies.
- Hyderabad Facilities (Telangana): Syngene discovery services campus and specialized synthetic API and peptide development laboratories.
- Johor Facility (Malaysia): Asia’s largest integrated recombinant human insulin and insulin analogs manufacturing site, featuring end-to-end drug substance synthesis and drug product fill-finish; currently undergoing a major expansion to double capacity.
- Cranbury Facility (New Jersey, USA): Commercial-scale oral solid dosage (OSD) formulation plant operationalized in FY26 to strengthen U.S. supply chain resilience.
- Biocon Academy (Bengaluru): Specialized CSR-funded educational center delivering advanced bio-intelligence and biomanufacturing skill enhancement programs.
📊 The Financial Health: Biocon Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
Biocon’s multi-year performance reflects substantial capital deployment towards expanding its commercial footprint and integrating acquisition assets, paving the way for cash flow generation and operating leverage.
| Financial Metric (₹ Cr) | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | Latest YoY (%) |
|---|---|---|---|---|---|---|
| Total Income | 17,269.50 | 16,469.90 | 15,621.00 | 11,550.00 | 8,325.00 | +4.85% |
| Revenue from Operations | 16,927.00 | 15,261.70 | 14,755.00 | 11,174.00 | 8,184.00 | +10.91% |
| EBITDA | 3,797.80 | 4,374.50 | 4,164.20 | 2,887.60 | 2,182.90 | -13.18% |
| Profit Before Exceptional Items & Tax | 850.80 | 1,790.10 | 1,340.00 | 1,090.00 | 1,094.00 | -52.47% |
| Profit Attributable to Shareholders | 385.60 | 1,013.30 | 1,022.50 | 462.70 | 648.40 | -61.95% |
| Total Equity (Net Worth) | 36,621.50 | 27,712.50 | 19,783.70 | 17,866.90 | 8,432.50 | +32.15% |
| Total Assets | 63,650.60 | 58,797.30 | 56,070.70 | 52,042.80 | 20,394.00 | +8.25% |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
In FY26, Biocon recorded a consolidated Profit for the Year of ₹ 368.80 Crores (with Profit attributable to equity shareholders standing at ₹ 385.60 Crores), compared to ₹ 1,429.40 Crores in FY25. The prior year’s reported profitability included significant one-time gain items, such as exclusivity sales of generic Lenalidomide and a ₹ 1,057.30 Crore gain from the divestment of the Branded Formulations India (BFI) business to Eris Lifesciences. On a like-to-like baseline, core operating revenues grew 13% and core EBITDA expanded by 25% in FY26.
| Consolidated Statement of Profit & Loss Line Item | FY 2025-26 (₹ Cr) | FY 2024-25 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 16,927.00 | 15,261.70 | +10.91% |
| Other Income | 342.50 | 1,208.20 | -71.65% |
| Total Income | 17,269.50 | 16,469.90 | +4.85% |
| Cost of Materials Consumed | 5,277.60 | 4,276.70 | +23.40% |
| Purchases of Stock-in-Trade | 1,362.60 | 626.60 | +117.46% |
| Changes in Inventories of Finished Goods, WIP & Stock-in-Trade | (949.50) | 294.20 | N/M |
| Employee Benefits Expense | 3,508.00 | 3,144.40 | +11.56% |
| Finance Costs | 990.30 | 897.40 | +10.35% |
| Depreciation and Amortisation Expense | 1,956.70 | 1,687.00 | +15.99% |
| Other Expenses | 4,386.70 | 3,901.10 | +12.45% |
| Less: Recovery of Cost from Co-Development Partners | (113.70) | (147.60) | -22.97% |
| Total Expenses | 16,418.70 | 14,679.80 | +11.85% |
| Profit Before Tax & Exceptional Items | 850.80 | 1,790.10 | -52.47% |
| Exceptional Items (Net Gain / Loss) | (402.90) | 96.50 | N/M |
| Profit Before Tax (PBT) | 447.90 | 1,886.60 | -76.26% |
| Tax Expense (Current & Deferred) | 79.10 | 457.20 | -82.70% |
| Profit for the Year (PAT) | 368.80 | 1,429.40 | -74.20% |
| Attributable to: Shareholders of the Company | 385.60 | 1,013.30 | -61.95% |
| Attributable to: Non-Controlling Interests | (16.80) | 416.10 | N/M |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
Biocon’s consolidated balance sheet underwent a major deleveraging transformation in FY26. Total Equity surged by 32.15% to ₹ 36,621.50 Crores following successful equity capital infusions via Qualified Institutions Placements (QIPs) totaling ₹ 8,650.00 Crores. Net Debt was reduced by 18.81% to ₹ 10,416.80 Crores (down from ₹ 12,830.00 Crores in FY25), improving the Net Debt-to-EBITDA ratio to 2.7x and lowering the debt-to-equity ratio to 0.44.
| Consolidated Balance Sheet Schedule III Line Item | As at March 31, 2026 (₹ Cr) | As at March 31, 2025 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| ASSETS: Non-Current Assets | |||
| Property, Plant and Equipment | 9,472.80 | 8,708.20 | +8.78% |
| Capital Work-in-Progress (CWIP) | 4,612.70 | 4,101.70 | +12.46% |
| Right-of-Use Assets | 578.00 | 604.20 | -4.34% |
| Goodwill | 18,377.50 | 16,785.70 | +9.48% |
| Other Intangible Assets | 8,057.60 | 5,865.20 | +37.38% |
| Intangible Assets Under Development | 2,374.00 | 4,406.70 | -46.13% |
| Non-Current Financial Investments | 1,089.30 | 679.70 | +60.26% |
| Derivative Assets & Other Financial Assets | 638.90 | 255.70 | +149.86% |
| Deferred Tax & Income Tax Assets (Net) | 985.20 | 628.30 | +56.80% |
| Other Non-Current Assets | 284.80 | 475.70 | -40.13% |
| Total Non-Current Assets | 46,470.80 | 42,511.10 | +9.31% |
| ASSETS: Current Assets | |||
| Inventories | 6,085.70 | 4,931.10 | +23.41% |
| Current Financial Investments | 689.80 | 447.30 | +54.21% |
| Trade Receivables | 5,986.80 | 5,487.90 | +9.09% |
| Cash and Cash Equivalents | 2,416.50 | 3,227.10 | -25.12% |
| Bank Balances Other than Cash Equivalents | 777.10 | 893.10 | -12.99% |
| Derivative & Other Financial Assets (Current) | 336.80 | 552.30 | -39.02% |
| Other Current Assets | 887.10 | 747.40 | +18.69% |
| Total Current Assets | 17,179.80 | 16,286.20 | +5.49% |
| TOTAL ASSETS | 63,650.60 | 58,797.30 | +8.25% |
| EQUITY AND LIABILITIES: Equity | |||
| Equity Share Capital | 810.50 | 600.30 | +35.02% |
| Other Equity | 33,221.30 | 21,043.70 | +57.87% |
| Equity Attributable to Owners | 34,031.80 | 21,644.00 | +57.23% |
| Non-Controlling Interests | 2,589.70 | 6,068.50 | -57.33% |
| Total Equity (Net Worth) | 36,621.50 | 27,712.50 | +32.15% |
| LIABILITIES: Non-Current Liabilities | |||
| Non-Current Borrowings | 10,746.30 | 12,405.40 | -13.37% |
| Lease Liabilities (Non-Current) | 537.00 | 539.10 | -0.39% |
| Derivative & Other Financial Liabilities | 623.30 | 2,851.40 | -78.14% |
| Provisions, Deferred Tax & Other Liabilities | 1,053.30 | 955.10 | +10.28% |
| Total Non-Current Liabilities | 12,959.90 | 16,751.00 | -22.63% |
| LIABILITIES: Current Liabilities | |||
| Current Borrowings | 4,078.40 | 5,350.10 | -23.77% |
| Lease Liabilities (Current) | 72.40 | 67.40 | +7.42% |
| Trade Payables (MSME & Others) | 6,772.10 | 6,548.70 | +3.41% |
| Derivative & Other Financial Liabilities | 1,214.50 | 978.10 | +24.17% |
| Other Current Liabilities, Provisions & Tax Liabilities | 1,931.80 | 1,389.50 | +39.03% |
| Total Current Liabilities | 14,069.20 | 14,333.80 | -1.85% |
| Total Liabilities (Excluding Equity) | 27,029.10 | 31,084.80 | -13.05% |
| TOTAL EQUITY AND LIABILITIES | 63,650.60 | 58,797.30 | +8.25% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
Working capital efficiency metrics reflect the operational dynamics of managing biosimilar inventory ramp-ups alongside commercial scaling in advanced markets:
- Debtors Turnover / Days: Trade receivables stood at ₹ 5,986.80 Crores at year-end, representing an average collection period of 128 days (compared to 131 days in FY25), illustrating stable collection cycles across global payors and partners.
- Inventory Turnover / Days: Inventories increased to ₹ 6,085.70 Crores, translating to 294 inventory days (versus 262 days in FY25). This planned inventory build-up supported new product launches (Kirsty™, Bosaya™, Yesintek®) and ensured buffer stock for global commercial distribution.
- Current Ratio & Debt-Equity Ratio: Current Ratio improved to 1.22x (from 1.14x in FY25). The Debt-to-Equity ratio dropped significantly from 0.64x to 0.40x due to net debt reduction and equity base expansion.
- Schedule III Ratio Variance Explanations (>25% YoY Change):
- Debt-Equity Ratio (-37.5%): Decreased from 0.64 to 0.40 due to equity capital additions via QIPs and debt repayment.
- Net Profit Margin %: Decreased from 6% to 3% due to the inclusion of one-off divestment gains and Lenalidomide exclusivity revenues in FY25 that were non-recurring in FY26.
- Standalone Debt Service Coverage Ratio (DSCR) & Net Capital Turnover: Standalone ratio variations were driven by the complete settlement of NCDs and bridging commercial papers using QIP proceeds.
Cash Flow: Tracking the Money Movement
Biocon generated robust operating cash flows of ₹ 1,994.00 Crores in FY26, despite working capital deployments for biosimilar launches. Cash outflows were directed toward capital expenditure and balance sheet deleveraging.
| Consolidated Cash Flow Statement Summary | FY 2025-26 (₹ Cr) | FY 2024-25 (₹ Cr) | Latest YoY (%) |
|---|---|---|---|
| Net Cash Generated from Operating Activities | 1,994.00 | 4,061.20 | -50.90% |
| Purchase of Property, Plant & Equipment (CapEx) | 1,911.70 | 2,343.30 | -18.42% |
| Purchase of Intangible Assets & Development | (113.80) | (206.70) | -44.94% |
| Other Investing Cash Flows (Investments, Bank Deposits, M&A Proceeds) | (170.40) | 2,109.20 | N/M |
| Net Cash Used in Investing Activities | (2,082.10) | (234.10) | +789.41% |
| Proceeds from Equity Share Capital Issuance (Net of Costs) | 8,427.50 | 0.00 | N/M |
| Purchase of Minority Equity & Debentures of Subsidiary (BBL Integration) | (5,800.20) | 0.00 | N/M |
| Net Repayment / Proceeds of Borrowings & Leases | (2,597.40) | (1,130.60) | +129.74% |
| Interest & Dividends Paid | (953.50) | (717.10) | +32.97% |
| Net Cash Used in Financing Activities | (923.60) | (1,854.00) | -50.18% |
| Net Increase / (Decrease) in Cash & Cash Equivalents | (1,011.70) | 1,973.10 | N/M |
| Cash and Cash Equivalents at Beginning of Year | 2,923.80 | 919.50 | +217.98% |
| Foreign Exchange Effect on Cash Balances | 199.40 | 31.20 | +539.10% |
| Cash and Cash Equivalents at End of Year (Cash Flow Rec) | 2,111.50 | 2,923.80 | -27.78% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
Biocon maintains high investment intensity in scientific development and global manufacturing infrastructure, transitioning from large-scale greenfield construction to asset utilization and optimization:
- Capital Expenditure & CWIP: Total capital expenditure for FY26 stood at ₹ 1,911.70 Crores (comprising ₹ 1,797.90 Crores in PPE and ₹ 113.80 Crores in intangibles), compared to ₹ 2,343.30 Crores in FY25. Capital Work-in-Progress (CWIP) at year-end was ₹ 4,612.70 Crores, while Intangible Assets Under Development stood at ₹ 2,374.00 Crores. Major projects include the Malaysia insulin facility doubling and peptide production suites.
- Gross & Net R&D Expenditure: Gross R&D investment reached ₹ 982.10 Crores (representing ~8% of total revenues excluding Syngene). Net P&L R&D expense stood at ₹ 982.10 Crores (compared to ₹ 858.50 Crores in FY25), driving global filings for generic Semaglutide and advancing clinical programs in oncology and immunology.
- Section 134(3)(m) Foreign Exchange Earnings & Outgo (Standalone):
- Gross Foreign Exchange Earned: ₹ 1,052.30 Crores (up from ₹ 890.90 Crores in FY25).
- Gross Foreign Exchange Outflow: ₹ 836.40 Crores (compared to ₹ 788.60 Crores in FY25).
- Net Foreign Exchange Earnings: ₹ 215.90 Crores (up 111% from ₹ 102.30 Crores in FY25).
👥 Power & Control: Biocon Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
Biocon Limited is governed by a 9-member Board of Directors, comprising 2 Executive Directors, 2 Non-Executive Non-Independent Directors, and 5 Independent Directors (including 3 female directors, representing 33% Board gender diversity). The Board structure is outlined below:
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Kiran Mazumdar-Shaw | Executive Chairperson | 00347229 | Executive Director (Promoter) |
| Shreehas Pradeep Tambe | CEO & Managing Director (w.e.f. April 01, 2026) | 09796480 | Executive Director |
| Prof. Ravi Rasendra Mazumdar | Non-Executive Director | 00109213 | Non-Executive Non-Independent |
| Eric Vivek Mazumdar | Non-Executive Director | 09381549 | Non-Executive Non-Independent |
| Bobby Kanubhai Parikh | Independent Director (Audit & Risk Committee Chair) | 00019437 | Non-Executive Independent |
| Naina Lal Kidwai | Lead Independent Director (NRC & CSR/ESG Chair) | 00017806 | Non-Executive Independent |
| Rekha Mehrotra Menon | Independent Director (SRC Chair) | 02768316 | Non-Executive Independent |
| Nicholas Robert Haggar | Independent Director | 08518863 | Non-Executive Independent |
| Atul Dhawan | Independent Director | 07373372 | Non-Executive Independent |
| Kedar Narayan Upadhye | Chief Financial Officer (w.e.f. April 01, 2026) | KMP | Key Managerial Personnel |
| Rajesh U. Shanoy | Company Secretary & Compliance Officer | A16328 | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
As of March 31, 2026, Biocon’s paid-up equity share capital stood at ₹ 810.45 Crores (₹ 810.50 Crores rounded), divided into 1,62,09,07,773 equity shares of face value ₹ 5/- each. The expanded capital reflects the issuance of 13,63,63,635 shares via QIP tranches and 17,12,79,553 shares via preferential share-swaps to acquire minority stakes in Biocon Biologics Limited.
| Shareholder Category | Number of Equity Shares Held | % of Total Issued Shares |
|---|---|---|
| Promoter & Promoter Group | 72,80,24,176 | 44.91% |
| Mutual Funds, Banks, & Domestic Financial Institutions | 39,01,31,473 | 24.07% |
| Foreign Portfolio Investors (FPIs) / FIIs | 12,19,32,372 | 7.52% |
| Corporate Bodies (Indian & Foreign, incl. Mylan Inc.) | 19,19,92,018 | 11.85% |
| Indian Public & Individual Retail Investors | 16,69,37,955 | 10.30% |
| NRIs & Foreign Nationals | 1,23,58,618 | 0.76% |
| Directors, Relatives, & Key Managerial Personnel | 76,76,375 | 0.47% |
| Trusts (Public & Employee Welfare Trusts) | 18,54,786 | 0.12% |
| Total Issued Shares | 1,62,09,07,773 | 100.00% |
- Significant Institutional Shareholders (>5% Stake): Kiran Mazumdar-Shaw holds 48,45,81,970 shares (29.90%); Glentec International Limited holds 23,72,11,164 shares (14.63%); SBI Large and Mid Cap Fund holds 13,29,91,285 shares (8.20%); Mylan Inc. holds 9,19,67,019 shares (5.67%).
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
In accordance with Section 129(3) of the Companies Act, 2013, the financial summary of key subsidiaries, associates, and joint ventures included in Biocon’s consolidated accounts is detailed below:
| Entity Name | Relationship Type | Country | % Shareholding | FY26 Revenue (₹ Cr) | FY26 Net Profit / (Loss) (₹ Cr) |
|---|---|---|---|---|---|
| Biocon Biologics Limited (BBL) | Subsidiary | India | 99.00% | 10,431.20 | 385.60 |
| Syngene International Limited | Subsidiary | India | 53.88% | 3,738.70 | 379.90 |
| Biocon Sdn. Bhd. | Subsidiary (via BBL) | Malaysia | 100.00% | 1,120.40 | 142.10 |
| Biocon Pharma Inc. | Subsidiary (via BL) | USA | 100.00% | 890.50 | 45.20 |
| Biocon Biologics Global PLC | Subsidiary (via BBL) | UK | 100.00% | 690.90 | 15.00 |
| NeoBiocon FZ LLC | Joint Venture | UAE | 50.00% | 0.00 | (0.60) |
| Bicara Therapeutics Inc. | Associate | USA | 10.10% | 0.00 | (58.40) |
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
- Strategic Quoted & Unquoted Investments: Quoted equity investments in Bicara Therapeutics Inc. valued at ₹ 1,027.10 Crores (55,23,897 shares) and Equillium Inc. valued at ₹ 43.30 Crores. Unquoted strategic investments include Immuneel Therapeutics (car-T cell therapies) and 6 renewable energy SPVs (50 MW solar & 34 MW wind captive projects) supporting net-zero targets.
- Credit Ratings & Banking Relationships: Maintained top-tier ratings across credit agencies: CRISIL (Crisil AA+/Stable & Crisil A1+), ICRA ([ICRA]AA+(Stable) / [ICRA]A1+), and India Ratings (IND AA+/Stable / IND A1+). Banking relationships include a consortium of domestic and global institutions (State Bank of India, HDFC Bank, HSBC, Citi, Mizuho, Bank of America).
- Contingent Liabilities & Capital Commitments:
- Direct Income Tax Matters under Dispute: ₹ 749.70 Crores (disputed assessment matters pending at appellate forums).
- Indirect Tax & Excise Disputes: ₹ 137.40 Crores (service tax, custom duties, and GST claims).
- Other Legal Claims & Guarantees: ₹ 41.30 Crores in commercial claims; ₹ 5.40 Crores in bank performance guarantees.
- Capital Commitments: Estimated capital contracts remaining to be executed (net of advances) stand at ₹ 1,023.80 Crores for property, plant, and equipment.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
- Interchangeable Biosimilar Portfolio Moat: Biocon holds first-mover status in securing U.S. FDA interchangeable status for both long-acting (Insulin Glargine) and rapid-acting (Insulin Aspart) insulins, establishing a high technical and regulatory barrier to entry.
- Dual Diabesity Positioning: Biocon is the only company globally possessing both commercial-scale biosimilar insulins and generic GLP-1 peptide capabilities (Liraglutide, Semaglutide), spanning the full spectrum of diabetes and obesity care.
- Cost Leadership via Vertical Integration: In-house fermentation capabilities, backward-integrated drug substance plants in Bengaluru, Visakhapatnam, and Malaysia, and dedicated fill-finish lines drive lower unit costs and supply reliability.
- Global Direct Commercial Infrastructure: Following the Viatris integration, Biocon controls commercialization, pricing, and payor engagements across 120+ markets, retaining commercial margins.
What Could Go Wrong? Key Challenges & Business Risks
- Regulatory Enforcement & cGMP Compliance: Facilities are subject to inspections by the U.S. FDA, EMA, and national regulators. Delays in site re-inspections or Form 483 observations could impact product launch timelines.
- Pricing Pressures & Tender Volatility: Biosimilars and generic formulations face price erosion in competitive tender markets (Europe, LATAM) and PBM commercial channels in the U.S.
- IP & Patent Litigation Risks: Launching biosimilars involves patent litigation with innovator companies. Settling IP disputes (e.g., with Regeneron, Bayer, Amgen) is critical for entry.
- Geopolitical & Foreign Exchange Fluctuations: Operating across 120+ markets exposes revenues to currency volatility (USD, EUR, MYR) and geopolitical disruptions in trade routes.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Biocon’s medium-term strategy focuses on commercial execution, operational leverage, and pipeline progression:
- Unlocking Diabesity (GLP-1 Expansion): Commercializing generic Liraglutide across additional European territories, followed by regulated market entries for generic Semaglutide as patent exclusivities expire.
- Ramp-Up of Recent Biosimilar Launches: Driving market adoption for newly launched biosimilars—Yesintek® (Ustekinumab), Yesafili® (Aflibercept), Bosaya™ / Aukelso™ (Denosumab), and Kirsty™ (Insualin Aspart).
- Next-Wave Oncology Pipeline: Advancing development programs for trastuzumab subcutaneous (SC), biosimilar Nivolumab, and biosimilar Pembrolizumab.
- Asset Utilization & Deleveraging: Maximizing throughput at the Cranbury OSD facility and expanded Malaysia insulins plant, while generating free cash flow to further reduce net debt.
The Verdict: Strategic Outlook & Conclusion
Biocon Limited has completed a multi-year transformation from a regional biopharmaceutical producer to a globally integrated, access-led biopharmaceutical enterprise. The consolidation of Biocon Biologics into OneBiocon simplifies its corporate architecture, strengthens its balance sheet, and enhances earnings visibility. Backed by its dual positioning in insulins and GLP-1 peptides, a commercial portfolio of 12 biosimilars, and a deleveraged capital structure, Biocon is positioned to capture market share across chronic disease management markets globally.
Frequently Asked Questions (FAQs) About Biocon
Q1: What does Biocon manufacture and what are its flagship brands?
Biocon manufactures biosimilars, recombinant human insulins, complex generic formulations, synthetic and fermentation APIs, and GLP-1 peptides. Flagship brands include Semglee® / Basalog® (biosimilar Insulin Glargine), Kirsty™ (biosimilar Insulin Aspart), Ogivri® (biosimilar Trastuzumab), Fulphila® (biosimilar Pegfilgrastim), Yesintek® (biosimilar Ustekinumab), Yesafili® (biosimilar Aflibercept), Bosaya™ (biosimilar Denosumab), and generic Liraglutide / Semaglutide.
Q2: What were Biocon’s revenue and net profit in FY 2025-26?
In FY 2025-26, Biocon generated a consolidated Revenue from Operations of ₹ 16,927.00 Crores (Total Income of ₹ 17,269.50 Crores) and an EBITDA of ₹ 3,797.80 Crores. Consolidated Profit for the Year (PAT) stood at ₹ 368.80 Crores, with Profit attributable to equity shareholders standing at ₹ 385.60 Crores.
Q3: Who are the promoters and Managing Director of Biocon?
Biocon was founded by Executive Chairperson Kiran Mazumdar-Shaw. The promoter group includes Kiran Mazumdar-Shaw, Prof. Ravi Rasendra Mazumdar, Dev Mazumdar, and Glentec International Limited, holding 44.91% of equity capital. Shreehas Pradeep Tambe serves as Chief Executive Officer & Managing Director effective April 01, 2026.
Q4: Where are Biocon’s manufacturing plants located and what is its export share?
Biocon operates manufacturing facilities in Bengaluru (Karnataka), Visakhapatnam (Andhra Pradesh), Hyderabad (Telangana), Johor (Malaysia), and Cranbury (New Jersey, USA). International markets account for 94.58% of consolidated operating revenues, with the U.S. contributing 47.23% and Europe/UK contributing 27.27%.
Q5: What is Biocon’s debt profile, credit rating, and net worth?
As of March 31, 2026, Biocon’s Total Equity (Net Worth) stood at ₹ 36,621.50 Crores. Net Debt was reduced to ₹ 10,416.80 Crores, bringing the Net Debt-to-EBITDA ratio down to 2.7x and the Debt-to-Equity ratio to 0.40x. Biocon maintains domestic long-term credit ratings of CRISIL AA+/Stable, [ICRA]AA+(Stable), and IND AA+/Stable.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.biocon.com